Deciphera Pharmaceuticals Stock News

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors. Deciphera will implement an organ

Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect DCPH stock to remain a clear-cut "avoid" situation.

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

The trading price of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) closed higher on Monday, November 22, closing at $8.66, 1.88% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has been assigned a consensus recommendation of Hold from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month []

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

(RTTNews) - Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. The approval is

QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study - Deciphera Pharmaceuticals, Inc. (NAS

The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prio

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagshi

Equities analysts expect Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) to report $23.44 million in sales for the current quarter, according to Zacks. Seven analysts have made estimates for Deciphera Pharmaceuticals earnings. The lowest sales estimate is $19.46 million and the highest is $27.11 million. Deciphera Pharmaceuticals reported sales of $19.49 million in the same quarter last year, []

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip. The post Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First